Exabis Library
Welcome to the e-CCO Library!
DOP67: A transcriptional module associated with neutrophil degranulation is highly conserved across species and is a core molecular pathway of treatment resistance in ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP67: Comparison of the pharmacokinetics of CT-P13 between Crohn’s Disease and Ulcerative Colitis in biologic-naïve patients; a prospective multi-center observational study of the KASID
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP67: First-line infliximab is cost-effective compared to conventional treatment in paediatric Crohn’s Disease – Results from the TISKids study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP67: Magnification endoscopy with optical chromoendoscopy for in vivo assessment of histological inflammation in patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP68 Thiomyristoyl ameliorates colitis by blocking the differentiation of Th17 cells via STAT3/IL-6 signal pathway
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP68: Assessment of patients' understanding of Inflammatory Bowel Diseases (IBD): Development and validation of a questionnaire (U-IBDQ)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP68: Autophagy induction in the intestinal epithelium protects against inflammation-induced barrier loss in vivo.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP68: CD-TREAT diet induces remission and improves quality of life in an open label trial in children and adults with active Crohn’s Disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP68: Histological remission (NANCY index) is superior to endoscopic mucosal healing in predicting relapse-free survival in patients with ulcerative colitis in clinical and endoscopic remission
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP69 Tofacitinib in ulcerative colitis: Early ‘real-world’ experience from four UK tertiary centres
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP69: Glycans as an actor in the microbiome-immune response crosstalk.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP69: Long-term outcome of infantile and very early onset IBD: A multi-center study from the IBD Porto group of ESPGHAN
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP69: Ozanimod for induction treatment of Moderate-to-Severe Ulcerative Colitis: Results from a systematic literature review and network meta-analyses
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP69: The detection with targeted biopsy and characterisation of neoplastic lesions by magnifying chromoendoscopy and NBI in surveillance colonoscopy of patients with ulcerative colitis: a sub-analysis of the Navigator Study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP70 High-dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP70: An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP70: Anti-TNF withdrawal according to a risk-stratified protocol does not reduce the risk of relapse in patients with Inflammatory Bowel Disease in endoscopic remission: A prospective study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP70: Crohn's Disease Like Inflammation of The Pouch is a Distinct Type of Pouchitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP70: Exosomes derived from human umbilical cord mesenchymal stem cells to attenuate colitis through repairing intestinal mucosal barrier
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP71 Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: Results from, UniStar, a phase 1 study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM